case_images: PMC7537502_01
case_images: Computed tomography of a 63-year-old man on the day of admission for respiratory failure due to COVID-19 pneumonia. The scan of the chest shows a crazy paving pattern.
case_images: AMS2-7-e585-g001.jpg
case_images: PMC7537502_01_AMS2-7-e585-g001.jpg
case_images: ams2585-fig-0001
case_images: On admission, computed tomography of the chest showed a crazy paving pattern (Fig. 1).
case_images: Timeline of clinical features and laboratory findings in a 63-year-old man with respiratory failure due to COVID-19 pneumonia. Nafamostat was discontinued after 4 days (black arrow) due to hyperkalemia and hemothorax. ECMO, extracorporeal membrane oxygenation.
case_images: AMS2-7-e585-g002.jpg
case_images: PMC7537502_01_AMS2-7-e585-g002.jpg
case_images: ams2585-fig-0002
case_images: Because V-V ECMO could not oxygenate his blood, replacement of the ECMO membrane was required 4 days after the initial V-V ECMO insertion (Fig. 2, first black triangle). Blood tests showed that fibrinogen had decreased while D-dimer had not increased with the combination therapy (Fig. 2). On day 15, the patient developed hyperkalemia (potassium, 6.5 mEq/L) and hemothorax; thus, nafamostat infusion was stopped (Fig. 2, black arrow). However, ECMO membrane exchange was needed on days 17 and 28 (Fig. 2).